Name: Merck & Co. Inc. (NYSE:MRK) | Analysis of Revenues
Creator: Stock Analysis on Net

Analysis of Revenues

Revenues as Reported

Revenues as Reported

Merck & Co. Inc., income statement, revenues

US$ in millions

12 months ended:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Pharmaceutical segment sales	57,400)	53,583)	52,005)	42,754)	43,021)
Animal Health segment sales	5,877)	5,625)	5,550)	5,568)	4,703)
Other segment sales	—)	—)	—)	—)	23)
Segment sales	63,277)	59,208)	57,555)	48,322)	47,747)
Other	891)	907)	1,728)	382)	247)
Sales	64,168)	60,115)	59,283)	48,704)	47,994)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Pharmaceutical Segment Sales: Pharmaceutical segment sales showed a generally positive trend over the observed period. Initially, sales decreased slightly from 43,021 million USD in 2020 to 42,754 million USD in 2021. However, a notable recovery and growth followed, with sales increasing to 52,005 million USD in 2022, continuing upward to 53,583 million USD in 2023, and reaching 57,400 million USD in 2024. This reflects a strong rebound and sustained growth in this core business area after the initial dip.
Animal Health Segment Sales: Animal health segment sales exhibited a consistent upward trend. Sales rose steadily from 4,703 million USD in 2020 to 5,568 million USD in 2021, with a slight decrease to 5,550 million USD in 2022. Thereafter, the segment experienced renewed growth, with sales figures climbing to 5,625 million USD in 2023 and further to 5,877 million USD in 2024. Overall, this segment demonstrated resilience and a steady expansion over the period.
Other Segment Sales: Other segment sales were reported only in 2020, amounting to 23 million USD, after which no data was provided for the subsequent years. This suggests either discontinuation of this segment, reclassification, or unavailability of data.
Total Segment Sales: Total segment sales reflect a clear growth trajectory, increasing from 47,747 million USD in 2020 to 48,322 million USD in 2021, followed by a more pronounced rise to 57,555 million USD in 2022. This upward trend continued with total segment sales growing to 59,208 million USD in 2023 and 63,277 million USD in 2024, indicating overall expansion across business segments.
Other Revenues: Other revenue categories showed significant variability. Starting at 247 million USD in 2020, there was an increase to 382 million USD in 2021, followed by a sharp jump to 1,728 million USD in 2022. This was succeeded by a decline to 907 million USD in 2023 and a slight decrease to 891 million USD in 2024. Such fluctuations suggest irregular contributions from auxiliary business activities or non-recurring items during this period.
Total Sales: Total sales, combining all revenue sources, demonstrated steady growth throughout the period. Sales increased from 47,994 million USD in 2020 to 48,704 million USD in 2021, then experienced substantial growth to 59,283 million USD in 2022. Growth continued at a slower but steady pace with sales reaching 60,115 million USD in 2023 and 64,168 million USD in 2024. This indicates successful revenue expansion largely driven by segment sales, particularly within the pharmaceutical segment.
Summary of Trends: The data reveals an overall positive sales growth trajectory over the five-year period, with the pharmaceutical segment as the primary growth driver. The animal health segment also contributed steady incremental gains. Other segment sales ceased to be reported after 2020. Total segment sales and total company sales grew significantly, especially from 2021 to 2022. While other revenues showed considerable volatility, their impact on total sales was relatively limited. These trends suggest a strong emphasis on the main pharmaceutical and animal health businesses as key revenue sources.

Download chart